| |
| | Patent 6,713,087 |
 | | A "labile agent" as that term is used herein, is a protein, polypeptide or oligonucleotide, or the pharmaceutically acceptable salt thereof, which is in its molecular, biologically active form when released in vivo, thereby possessing the desired therapeutic, prophylactic and/or diagnostic properties in vivo. |
 | | The labile agent can be stabilized against degradation, loss of potency and/or loss of biological activity, all of which can occur during formation of the micron particles, during formation of the sustained release composition having the micron particles dispersed therein, and/or prior to and during in vivo release of the labile agent. |
 | | First, the labile agent can be released by diffusion through aqueous filled channels generated in the polymer matrix, such as by the dissolution of the labile agent, or by voids created by the removal of the polymer solvent during the preparation of the sustained release composition. |
| www.pharmcast.com /Patents100/Yr2004/Mar2004/033004/6713087_Labile033004.htm (4804 words) |
|